RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Mar 4, 2013 - 12:45:42 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Pediatric cancer charities partner to fund international collaborative research

Mar 4, 2013 - 5:00:00 AM
This collaboration is significant, not only because of the amount of funding but also because we are creating more access to clinical trials for children, said Richard Brown, Chair at J-A-C-K. Alliances can bring new ideas; focus new energies; and produce new action to defeat a cancer that preys upon the youngest. By bringing together both the advocacy community and the scientific community to work across continents, we can only maximize the hope that options such as immunotherapy may offer to children affected by neuroblastoma.

 
[RxPG] Solving Kids' Cancer, along with U.K.-based charities Neuroblastoma Alliance UK, J-A-C-K, and other European organizations have aligned forces to improve access to promising clinical trials for children with high-risk neuroblastoma in North America, the U.K. and Europe. The aim of the International Neuroblastoma Research Collaborative (INBRC) is to bring the cancer research community together to produce immunotherapy options to treat, control and prevent the recurrence of neuroblastoma in children. The new initiative mandates a collaboration of international cancer centers, offering a grant award of up to $500,000 (USD).

The pediatric cancer charities have partnered for the first time to create new treatments for children with neuroblastoma who at best, have a 5 percent chance of survival after relapse.

Neuroblastoma is a cancer of the sympathetic nervous system that most commonly occurs in infants and children under 5 years old. The cancer is usually discovered after it has spread. Half of all children are diagnosed with high-risk neuroblastoma, which is one of the most aggressively treated of all cancers. Standard treatments include months of chemotherapy, surgery, radiation, and stem cell transplant, followed by additional months of maintenance therapy.

Even after such intense treatment, about 60 percent of children relapse within three years, said Scott Kennedy, the Executive Director of Solving Kids' Cancer. Immunotherapy can offer these children less toxic and more effective treatments, and offers more potential of curing relapsed neuroblastoma than chemotherapy and radiation.

Immunotherapy for cancer has rapidly advanced in recent years and shown success in some adult cancers, but few options are available for children, especially in Europe.

This collaboration is significant, not only because of the amount of funding but also because we are creating more access to clinical trials for children, said Richard Brown, Chair at J-A-C-K. Alliances can bring new ideas; focus new energies; and produce new action to defeat a cancer that preys upon the youngest. By bringing together both the advocacy community and the scientific community to work across continents, we can only maximize the hope that options such as immunotherapy may offer to children affected by neuroblastoma.

Neuroblastoma Alliance UK's Chief Executive, Alison Moy, agreed, We are really excited to be involved in this collaboration, which is taking parent advocacy and the involvement of charities in furthering research to a new level. As neuroblastoma only affects children, it is not considered a common cancer and therefore research funding has been limited. We believe that children should be able to access the best possible treatment, wherever that may be and that's why we support families to access clinical treatment abroad. We hope that through the INBRC project, more children from the U.K. will be able get effective treatment, wherever that trial is taking place.



Related Latest Research News
How do consumers see a product when they hear music?
Drug activates virus against cancer
Bone loss associated with increased production of ROS
Sound preconditioning prevents ototoxic drug-induced hearing loss in mice
Crystal methamphetamine use by street youth increases risk of injecting drugs
Johns Hopkins-led study shows increased life expectancy among family caregivers
Moderate to severe psoriasis linked to chronic kidney disease, say experts
Licensing deal marks coming of age for University of Washington, University of Alabama-Birmingham
Simple blood or urine test to identify blinding disease
Physician job satisfaction driven by quality of patient care

Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)